[Update in treatment of psoriatic arthritis].
Psoriatic arthritis is a chronic rheumatic disease making part of spondylarthropathies. It is the most frequent chronic inflammatory rheumatism after rheumatoid arthritis. Eventhough, it is usually a benign affection, it may be destructive leading to handicap. Several new medications have been introduced, including anti-tumor necrosis factor (TNF alpha blockers) and leflunomide for treatment of psoriatic arthritis. Many studies show the efficacy of these medications in this disease.
Abdelmoula
Leila Cheikhrouhou
LC
Service de rhumatologie, Hôpital Charles Nicolle, Tunis, Tunisie.
Ben M'Barek
Rim
R
Yahia
Chiraz Ben Hadj
CB
Tekaya
Raoudha
R
Testouri
Nadia
N
Chaabouni
Lilia
L
Zouari
Rafik
R
D000068879:Adalimumab; D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use; D000077339:Leflunomide; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D003879:Dermatologic Agents; D007555:Isoxazoles; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D000077944:Alefacept; D000068879:Adalimumab; D000077339:Leflunomide